Histopathological evaluation of cutaneous malignant melanoma: A retrospective study

• Published in: Experimental and therapeutic medicine Vol. 23; no. 6; p. 402
• Main Authors: Gheoca Mutu, Daniela-Elena, Avino, Adelaida, Balcangiu-Stroescu, Andra-Elena, Mehedințu, Mihai, Bălan, Daniela Gabriela, Brîndușe, Lăcrămioara Aurelia, Popescu, Ana-Maria, Ionescu, Dorin, Cristea, Bogdan-Mihai, Tomescu, Luminiţa Florentina, Jecan, Cristian-Radu, Răducu, Laura
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.06.2022; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Biological markers; Biomarkers; Care and treatment; Cellular proteins; Chronic illnesses; Diagnosis; Disease; Genetic aspects; Health aspects; Identification and classification; Males; Medical prognosis; Melanoma; Metastasis; Mortality; Patients; Prognosis; Proteins; Skin cancer; Statistical analysis; Romania; evaluation; melanoma; immunohistochemistry; prognosis; biomarkers
• ISSN: 1792-0981; 1792-1015
• DOI: 10.3892/etm.2022.11329

Malignant melanoma is a melanocytic neoplasm with a steadily increasing incidence worldwide. In order to define a proper diagnostic protocol and to establish an accurate prognostic method for the disease, specific biomarkers are of notable importance. Their contribution is also significant in the treatment of melanoma for the improvement of newer and more targeted therapeutic approaches. To emphasize the importance of specific immune markers in the diagnosis of melanoma, immunohistochemical analysis was performed on 56 formalin-fixed paraffin-embedded cutaneous melanomas. Besides the traditional prognostic factors, depth of invasion and mitotic rate, the markers tested in the present study were S100 protein family, Melan A, Ki67 and HMB-45. The present results indicated that immunocytochemistry represents a valuable test in the diagnosis and treatment of malignant melanoma and each biomarker had different associations with the progression and prognosis of the disease. Patients with S100 expression were 4.83 times (95% CI=1.2-20.8) more likely to suffer a relapse, whereas patients with a Ki67 expression of >30% had a 5.41-fold higher risk (95% CI=1.3-22.0). The correlation between S100 and the Breslow depth was statistically significant (r-value: 0.43; P=0.027). In addition, the importance of a multidisciplinary team including a plastic surgeon, anatomopathologist and oncologist was highlighted.